Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial

• Published in: Cancer science Vol. 109; no. 6; pp. 1930 - 1938
• Main Authors: Akamatsu, Hiroaki, Katakami, Nobuyuki, Okamoto, Isamu, Kato, Terufumi, Kim, Young Hak, Imamura, Fumio, Shinkai, Masaharu, Hodge, Rachel A., Uchida, Hirohiko, Hida, Toyoaki
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.06.2018
• Subjects: Acrylamides; Adult; Aged; Aged, 80 and over; Anemia - chemically induced; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Asians - genetics; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - ethnology; Carcinoma, Non-Small-Cell Lung - genetics; Diarrhea - chemically induced; Disease-Free Survival; epidermal growth factor receptor; ErbB Receptors - genetics; Female; Humans; Japan; Japanese; Lung Neoplasms - drug therapy; Lung Neoplasms - ethnology; Lung Neoplasms - genetics; Male; Middle Aged; Mutation; non‐small‐cell lung cancer; Original; Pemetrexed - administration & dosage; Pemetrexed - adverse effects; Piperazines - adverse effects; Piperazines - therapeutic use; Platinum - administration & dosage; Platinum - adverse effects; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; tyrosine kinase; Young Adult; Japan; mutation; Japanese; epidermal growth factor receptor; tyrosine kinase; non-small-cell lung cancer

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the first‐line treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However, most patients become resistant to these drugs, so their disease progresses. Osimertinib, a third‐generation EGFR‐TKI that...